SimBioSys Achieves Second FDA Clearance for TumorSight™ Viz and Introduces TumorSight™ Clinical Decision Support for Breast Cancer Surgery

CHICAGO, Nov. 4, 2024 /PRNewswire/ — SimBioSys®, a pioneering TechBio company at the forefront of digital precision medicine for cancer care, is proud to announce its second FDA 510(k) clearance for TumorSight™ Viz to expand its use by breast surgeons across the US. The updated…

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.